Effector Therapeutics Inc (EFTR) — Capital Reinvestment Ratio

Latest as of December 2020: 0.01x

Effector Therapeutics Inc (EFTR) has a Capital Reinvestment Ratio of 0.01x as of December 2020, meaning it reinvests 0% of its operating cash flow ($13.84 Million) in capital expenditures ($154.00K). See EFTR equity financing ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.01x
Capex / Operating Cash Flow

Operating Cash Flow

$13.84 Million
USD

Capital Expenditures

$154.00K
USD

Data as of

Dec 2020
Most recent filing

Effector Therapeutics Inc Capital Reinvestment Ratio (2020–2020)

This chart tracks Effector Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. Check Effector Therapeutics Inc (EFTR) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Effector Therapeutics Inc (2020–2020)

Year-by-year Capital Reinvestment Ratio for Effector Therapeutics Inc from 2020 to 2020. For live market cap and broader valuation context, see EFTR market cap overview.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2020 0.01x $13.84 Million $154.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow